

# Oklahoma Health Care Authority

## Drug Utilization Review Board

### (DUR Board)

Meeting – October 12, 2022 @ 4:00pm

at the

Oklahoma Health Care Authority (OHCA)

4345 N. Lincoln Blvd.

Oklahoma City, Oklahoma 73105

**NOTE:**     ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

### **AGENDA**

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

#### **1. Call to Order**

A. Roll Call – Dr. Wilcox

#### **DUR Board Members:**

Dr. Jennifer de los Angeles –	participating in person
Ms. Jennifer Boyett –	participating in person
Dr. Megan Hanner –	participating in person
Dr. Lynn Mitchell –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person

#### **Viewing Access Only via Zoom:**

Please register for the meeting at:

[https://zoom.us/webinar/register/WN\\_73z8ERX7Sv-KeQGP3GVqPg](https://zoom.us/webinar/register/WN_73z8ERX7Sv-KeQGP3GVqPg)

After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:

Dial: +1-602-753-0140 or +1-669-219-2599

Webinar ID: 952 7560 1667

Passcode: 69395211

## **Public Comment for Meeting:**

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at [www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board](http://www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board) and completing the [Speaker Registration Form](#). Completed Speaker Registration forms should be submitted to [DURPublicComment@okhca.org](mailto:DURPublicComment@okhca.org). Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

### **2. Public Comment Forum**

- A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

### **3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**

- A. July 13, 2022 DUR Board Meeting Minutes
- B. July 13, 2022 DUR Board Recommendations Memorandum
- C. August 10, 2022 DUR Board Recommendations Memorandum
- D. September 14, 2022 DUR Board Meeting Minutes
- E. September 14, 2022 DUR Board Recommendations Memorandum

Items to be presented by Dr. O'Halloran, Dr. Teel, Dr. Muchmore, Chairman:

### **4. Update on Medication Coverage Authorization Unit/Fall 2022 Pipeline Update – See Appendix B**

- A. Pharmacy Helpdesk Activity for September 2022
- B. Medication Coverage Activity for September 2022
- C. Fall 2022 Pipeline Update

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

### **5. Action Item – Approval of September 2022 DUR Board Recommendations – See Appendix C**

- A. Vote to Update the Approval Criteria for the Ophthalmic Anti-Inflammatory Products
  - i. College of Pharmacy Recommendations
- B. Vote to Prior Authorize Recorlev® (Levoketoconazole) and Update the Approval Criteria for Isturisa® (Osilodrostat)

- i. Market News and Updates
  - ii. Recorlev® (Levoketoconazole) Product Summary
  - iii. College of Pharmacy Recommendations
- C. Vote to Prior Authorize Tlando® (Testosterone Undecanoate) and Update the Approval Criteria for the Testosterone Products
  - i. Market News and Updates
  - ii. Cost Comparison
  - iii. College of Pharmacy Recommendations
- D. Vote to Update the Approval Criteria for the Opioid Analgesics and Medication-Assisted Treatment (MAT) Medications
  - i. Market News and Updates
  - ii. College of Pharmacy Recommendations
- E. Vote to Prior Authorize Adlarity® (Donepezil Transdermal System) and Aduhelm® (Aducanumab-awwa)
  - i. Market News and Updates
  - ii. Aduhelm® (Aducanumab-awwa) Product Summary
  - iii. College of Pharmacy Recommendations
- F. Vote to Update the Approval Criteria for the Topical Corticosteroids
  - i. College of Pharmacy Recommendations
- G. Vote to Prior Authorize Camzyos™ (Mavacamten)
  - i. Market News and Updates
  - ii. Camzyos™ (Mavacamten) Product Summary
  - iii. College of Pharmacy Recommendations
- H. Vote to Update the Approval Criteria for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators
  - i. Market News and Updates
  - ii. College of Pharmacy Recommendations
- I. Vote to Prior Authorize Alymsys® (Bevacizumab-maly), Lonsurf® (Trifluridine/Tipiracil), and Stivarga® (Regorafenib) and Update the Approval Criteria for the Colorectal Cancer Medications
  - i. Market News and Updates
  - ii. Product Summaries
  - iii. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**6. Action Item – Vote to Prior Authorize Amvuttra™ (Vutrisiran) and Update the Approval Criteria for Amyloidosis Medications – See Appendix D**

- A. Market News and Updates
- B. Amvuttra™ (Vutrisiran) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**7. Action Item – Vote to Prior Authorize Herceptin Hylecta™ (Trastuzumab/Hyaluronidase-oysk) and Update the Approval Criteria for the Breast Cancer Medications – See Appendix E**

- A. Market News and Updates
- B. Herceptin Hylecta™ (Trastuzumab/Hyaluronidase-oysk) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**8. Action Item – Annual Review of Bylvay® (Odevixibat) and Livmarli® (Maralixibat) – See Appendix F**

- A. Current Prior Authorization Criteria
- B. Utilization of Bylvay® (Odevixibat) and Livmarli® (Maralixibat)
- C. Prior Authorization of Bylvay® (Odevixibat) and Livmarli® (Maralixibat)
- D. Market News and Updates
- E. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

**9. Action Item – Annual Review of Spinal Muscular Atrophy (SMA) Medications – See Appendix G**

- A. Current Prior Authorization Criteria
- B. Utilization of SMA Medications
- C. Prior Authorization of SMA Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of SMA Medications

Items to be presented by Dr. Borders, Dr. Muchmore, Chairman:

**10. Annual Review of Myeloproliferative Neoplasm (MPN) Medications and 30-Day Notice to Prior Authorize Besremi® (Ropeginterferon Alfa-2b-njft) and Vonjo® (Pacritinib) – See Appendix H**

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of MPN Medications
- D. Prior Authorization of MPN Medications
- E. Market News and Updates
- F. Product Summaries
- G. College of Pharmacy Recommendations
- H. Utilization Details of MPN Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

**11. Annual Review of Targeted Immunomodulator Agents and 30-Day Notice to Prior Authorize Sotyktu™ (Deucravacitinib), Spevigo® (Spesolimab-sbzo), and Tavneos® (Avacopan) – See Appendix I**

- A. Current Prior Authorization Criteria
- B. Utilization of Targeted Immunomodulator Agents
- C. Prior Authorization of Targeted Immunomodulator Agents
- D. Market News and Updates
- E. Product Summaries

- F. College of Pharmacy Recommendations
- G. Utilization Details of Targeted Immunomodulator Agents

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**12. Annual Review of Anemia Medications and 30-Day Notice to Prior Authorize Enjaymo™ (Sutimlimab-jome), Pyrukynd® (Mitapivat), and Zynteglo® (Betibeglogene Autotemcel) – See Appendix J**

- A. Current Prior Authorization Criteria
- B. Utilization of Anemia Medications
- C. Prior Authorization of Anemia Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Anemia Medications

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

**13. Annual Review of Hepatitis C Medications – See Appendix K**

- A. Current Prior Authorization Criteria
- B. Utilization of Hepatitis C Medications
- C. Prior Authorization of Hepatitis C Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Hepatitis C Medications

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

**14. 30-Day Notice to Prior Authorize Xenpozyme® (Olipudase Alfa-rpcp)– See Appendix L**

- A. Introduction
- B. Xenpozyme® (Olipudase Alfa-rpcp) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

**15. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix M**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

**16. Future Business\* (Upcoming Product and Class Reviews)**

- A. Asthma and Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications
- B. Atopic Dermatitis Medications
- C. Multiple Myeloma Medications
- D. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Medications

\*Future product and class reviews subject to change.

## **17. Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.